Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technology Applied for Molecular Testing Outside of Central Laboratories

By LabMedica International staff writers
Posted on 16 Apr 2012
A collaborative program has been initiated to develop assays utilizing the new Discipher system for bringing DNA-based testing and diagnostics to point-of-care settings.

Discipher is a low cost, walk-away system, based on DVD technology. More...
It uses self-contained, disposable assay devices in the form of DVD discs with microfluidic channels. The system was jointly developed by UK-based scientific engineering company Plarion Ltd. (Hertfordshire, UK) and the Scandinavian diagnostics technology development company LingVitae Corporation (Oslo, Norway). This work was supported by funding from the Seventh Research Framework Program of the European Union, under the Digital Sequencing project.

The new research and development collaboration will bring in the Sweden-based technical university KTH Royal Institute of Technology (KTH; Stockholm, Sweden). As part of this engagement, LingVitae/Plarion will transfer prototype versions of the Discipher instrument to the researchers at KTH, as well as support the development work by customizing the optical disc-based disposable assay devices.

“Our aim with Discipher is to democratize molecular and cellular analysis, putting low-cost easy-to-use tools in the hands of the wider community, outside of core laboratories”, said Dr. Jackie Cole, Head of Marketing for Plarion. “We see that the Discipher system addresses an unmet need in bringing DNA-based diagnostics and testing to users who have previously not had access to this technology,” says Prof. Lundeberg, based at the Science for Life Laboratory in Stockholm.

Dr. Preben Lexow, Chief Executive Officer of LingVitae, added, “We look forward to the collaboration with Professor Lundeberg’s group [at KTH]. The track-record of KTH on development of DNA-based assays, utilizing a repertoire of molecular techniques, provides an exciting opportunity for us to expand our activities in the DNA assay space.”

The innovative Discipher system - with its integrated temperature control, centrifuge, and high-resolution readout - is well suited for point-of-care assays requiring minimal end user operation, rapid turnaround times, and ability to multiplex tests. Assay developers, especially in the areas of immune and cellular assays, are encouraged to contact LingVitae to discuss collaborations or assay transfers to the Discipher system.

Related Links:

KTH Royal Institute of Technology
LingVitae Corporation
Plarion Ltd.




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.